Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Loss of PTEN Expression Is Associated With IGFBP2 Expression, Younger Age, and Late Stage in Triple-Negative Breast Cancer

(2014) Sarah J. R. Dean et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment

(2013) Y H Park et al.   BRITISH JOURNAL OF CANCER

Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues

(2013) Oscar Maiques et al.   HUMAN PATHOLOGY

Comprehensive analysis of PTEN status in breast carcinomas

(2013) Natalie Jones et al.   INTERNATIONAL JOURNAL OF CANCER

Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial

(2013) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN

(2013) Yanyuan Wu et al.   PLoS One

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

(2013) John Stagg et al.   Therapeutic Advances in Medical Oncology

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

(2012) F. Andre et al.   ANNALS OF ONCOLOGY

Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype

(2012) Brenda Deyarmin et al.   ANNALS OF SURGICAL ONCOLOGY

Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities

(2012) D. W. Craig et al.   MOLECULAR CANCER THERAPEUTICS

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

(2011) E. Razis et al.   BREAST CANCER RESEARCH AND TREATMENT

MGMT and PTEN as potential prognostic markers in breast cancer

(2011) Julio Cirullo Neto et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study

(2010) Dalal M Al Tamimi et al.   BMC CANCER

Management of breast cancer with targeted agents: importance of heterogenicity

(2010) Serena Di Cosimo et al.   Nature Reviews Clinical Oncology

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma

(2009) Alessandra Capodanno et al.   HUMAN PATHOLOGY

Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy

(2008) Kan Yonemori et al.   MEDICAL ONCOLOGY